$AIMAug 5, 2026, 12:13 PMAI processed8-K
AIM ends ATM with Maxim; no further ATM sales after Aug 15, 2026
AI Summary
AIM IMMUNOTECH INC. filed SEC Form 8-K. AIM ImmunoTech notified Maxim of mutual termination of its Equity Distribution (ATM) Agreement, effective August 15, 2026, meaning the company cannot sell additional common shares under that ATM after that date. From April 1, 2025 through July 31, 2026 the company sold 3,200,736 shares for aggregate gross proceeds of approximately $2.8M and says there are no termination penalties.
Positives
- Removes a dedicated channel for immediate at-the-market sell pressure after Aug 15, 2026
- Company already raised ~ $2.8M via 3.2M ATM share sales to date
- No termination penalties for ending the ATM
Negatives
- Loses near-term financing flexibility from the Maxim ATM (cannot tap this facility going forward)
- May need to pursue alternative, potentially more dilutive or costly, financing if capital is required
Filing Context
Filing and Dilution Context
Earliest dilution
Earliest dilution: Aug 15, 2026 close
Dilution status
delayed
Dilution timing
Dilution status: Delayed
Trigger type
closing
Trigger date
Aug 15, 2026